PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32852568-0	2021	The beneficial effects of reducing NLRP3 inflammasome activation in the cardiotoxicity and the anti-cancer effects of doxorubicin.	Doxorubicin	118-129	NLR family pyrin domain containing 3	Homo sapiens	35-40	
32852568-6	2021	Recent studies have suggested that the Nucleotide-Binding Domain-Like Receptor Protein 3 (NLRP3) inflammasome is implicated in tumor progression and the chemoresistance of cancer cells to DOX.	Doxorubicin	188-191	NLR family pyrin domain containing 3	Homo sapiens	39-88	
32852568-6	2021	Recent studies have suggested that the Nucleotide-Binding Domain-Like Receptor Protein 3 (NLRP3) inflammasome is implicated in tumor progression and the chemoresistance of cancer cells to DOX.	Doxorubicin	188-191	NLR family pyrin domain containing 3	Homo sapiens	90-95	
32852568-7	2021	Of interest, reducing NLRP3 inflammasome activity alleviates DOX-induced cardiotoxicity.	Doxorubicin	61-64	NLR family pyrin domain containing 3	Homo sapiens	22-27	
32852568-8	2021	Therefore, we postulate that strategies that target the NLRP3 inflammasome can help mitigate the cardiotoxic effects of DOX while maintaining and/or even enhancing its anti-cancer activity.	Doxorubicin	120-123	NLR family pyrin domain containing 3	Homo sapiens	56-61	
32852568-9	2021	Herein, we review the current knowledge about the potential implication of the NLRP3 inflammasome in the anti-cancer and cardiotoxic effects of DOX.	Doxorubicin	144-147	NLR family pyrin domain containing 3	Homo sapiens	79-84